Craig C. Hopkinson, the EVP R&D of $ALKS, sold 9,000 shares of the company on 10-15-2025 for an estimated $283,776. We received data on the trade from a recent SEC filing. This was a sale of approximately 10.9% of their shares of this class of stock. Following this trade, they now own 73,740 shares of this class of $ALKS stock.
$ALKS Insider Trading Activity
$ALKS insiders have traded $ALKS stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $ALKS stock by insiders over the last 6 months:
- CRAIG C. HOPKINSON (EVP R&D, Chief Medical Officer) sold 9,000 shares for an estimated $283,776
- CHRISTIAN TODD NICHOLS (SVP, Chief Commercial Officer) has made 0 purchases and 2 sales selling 6,667 shares for an estimated $210,143.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ALKS Hedge Fund Activity
We have seen 182 institutional investors add shares of $ALKS stock to their portfolio, and 182 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP removed 2,202,409 shares (-32.0%) from their portfolio in Q2 2025, for an estimated $63,010,921
- BAKER BROS. ADVISORS LP added 1,927,318 shares (+43.0%) to their portfolio in Q2 2025, for an estimated $55,140,567
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,746,345 shares (-14.8%) from their portfolio in Q2 2025, for an estimated $49,962,930
- UBS GROUP AG removed 1,700,807 shares (-55.9%) from their portfolio in Q2 2025, for an estimated $48,660,088
- WELLINGTON MANAGEMENT GROUP LLP removed 1,396,776 shares (-45.1%) from their portfolio in Q2 2025, for an estimated $39,961,761
- PARADIGM BIOCAPITAL ADVISORS LP added 1,375,569 shares (+inf%) to their portfolio in Q2 2025, for an estimated $39,355,029
- BNP PARIBAS FINANCIAL MARKETS added 1,007,488 shares (+787.2%) to their portfolio in Q2 2025, for an estimated $28,824,231
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALKS Analyst Ratings
Wall Street analysts have issued reports on $ALKS in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 09/26/2025
- Needham issued a "Buy" rating on 07/29/2025
- Goldman Sachs issued a "Buy" rating on 07/15/2025
- UBS issued a "Buy" rating on 06/17/2025
- Baird issued a "Outperform" rating on 05/02/2025
To track analyst ratings and price targets for $ALKS, check out Quiver Quantitative's $ALKS forecast page.
$ALKS Price Targets
Multiple analysts have issued price targets for $ALKS recently. We have seen 8 analysts offer price targets for $ALKS in the last 6 months, with a median target of $43.5.
Here are some recent targets:
- Leonid Timashev from RBC Capital set a target price of $44.0 on 09/26/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $46.0 on 09/09/2025
- Jessica Fye from JP Morgan set a target price of $35.0 on 09/09/2025
- Benjamin Burnett from Wells Fargo set a target price of $44.0 on 09/03/2025
- Ami Fadia from Needham set a target price of $45.0 on 07/29/2025
- Andrea Newkirk from Goldman Sachs set a target price of $43.0 on 07/15/2025
- Ashwani Verma from UBS set a target price of $42.0 on 06/17/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
